Purchase Order 75N95018P00630
- Not listed
- The U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse (NIDA) awarded a firm-fixed-price purchase order contract to Chemaxon LLC, a for-profit limited liability company, to provide chemistry software and related support services. The $367,001.56 contract, which runs from September 30, 2024 to September 29, 2029, will deliver the Chemaxon chemistry software suite, including products such as JChem Oracle Cartridge, Marvin JS, JChem Base,...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) under the Department of Health and Human Services, awarded a firm-fixed-price purchase order contract to Chemaxon LLC for annual license renewals of the JChem Oracle Cartridge and Marvin JS software. The $56,418.00 contract will provide the AIMS (ATDP Information Management System) application with access to these critical cheminformatics tools from July 1, 2024 through June 30, 2025, with potential...
- This sole source contract awarded by the Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse to Chemaxon LLC is for annual license renewals of JChem Oracle Cartridge and Marvin JS software. Valued at $10,490, the firm fixed price contract provides 100 user licenses for both the JChem Oracle Cartridge and Marvin JS Library from July 1, 2023 through June 30, 2024 with an additional four 12-month option periods. The software licenses are...
- This is a $80,400.00 firm fixed price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Axon Medchem B.V., a foreign-owned for-profit organization. The contract is for the Small Molecules for NCATS Pharmacologically Active Chemical Toolbox (NPACT) program, which aims to provide small molecule compounds. The contract has an ultimate completion date of July 25, 2015 and was awarded on April 24, 2015. There was no set-aside designation used for...
- The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, awarded a $87,500.00 firm-fixed-price purchase order to Chemaxon LLC for a 5-year renewal and support of cheminformatics software licenses. The software, which includes products like JChem Oracle Cartridge, Marvin JS, and Instant JChem Enterprise, supports NCATS' initiatives in biotechnology and pharmaceutical research, such as the Preclinical Screening Platform...
- The U.S. Patent and Trademark Office awarded Chemaxon LLC a firm fixed-price purchase order valued at $867,326 for cheminformatics software and maintenance support. The contract, which commenced on August 11, 2025, extends through August 10, 2028, and will be performed at the vendor's location in Lynnfield, Massachusetts. No small business set-aside was utilized for this award. Chemaxon LLC, a specialized software company focused on advanced chemistry and molecular informatics tools, will...
- This is a $90,000.00 firm fixed price purchase order awarded by the National Institute on Drug Abuse (NIDA), which is a civilian agency of the U.S. government. The contract, which does not have a set-aside designation, is for the "SMALL MOLECULES FOR NCATS PHARMACOLOGICALLY ACTIVE CHEMICAL TOOLBOX (NPACT)" program and was awarded to DC Chemicals LIMITED, a for-profit limited liability company, on July 9, 2015. The period of performance for this contract ends on November 30, 2015.
- This is a firm fixed price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the Department of Health and Human Services, to Mestrelab Research SL, a foreign-owned for-profit software company. The contract is for the provision of Mestrelab's Mnova software suite, including NMR, LC/MS, and other analytical chemistry applications, as well as associated software licenses and deployment services. The contract has a ceiling value of $9,709.37 and...
- This is a $146,500.00 purchase order contract awarded by the National Library of Medicine (NLM) to Xemistry GMBH, a foreign-owned for-profit organization, for software support and maintenance of the CACTVS Chemoinformatics Toolkit. The contract has a base period of performance from July 20, 2023 through July 19, 2026, with no set-aside designation. This contract was awarded under the authority of Federal Acquisition Regulation (FAR) Simplified Acquisition Procedures, as Xemistry GMBH is the sole...
- Chemaxon LLC has been awarded a $23,865 firm fixed price purchase order by the National Institutes of Health's National Institute of Neurological Disorders and Stroke to provide Chemaxon software licenses for use across the NIH's Protein Structure Prediction Pipeline and Enhanced Therapeutics Structure Prediction programs through September 2024. The licenses will support the NIH's efforts to advance understanding of neurological disorders and develop new treatments. As the prime contractor,...
This is a $90,800.00 firm-fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services, to Chemaxon LLC, a foreign-owned for-profit limited liability company. The contract, which has a completion date of September 29, 2023, is for the provision of ChemAxon software licenses, including JChem Oracle Cartridge, Marvin JS, JChem Base, and Instant JChem Enterprise. These specialized cheminformatics tools are used to support NIDA's drug discovery and development initiatives, such as the Preclinical Screening Platform for Pain, Epilepsy Therapy Screening Program, and Addiction Treatment Drug Program Information Management System. The contract was set aside for small businesses.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00006 | Funding Only Action | ($23k) | 4/25/23 | |
| P00005 | Other Administrative Action | $0 | 12/21/22 | |
| P00004 | Exercise an Option | $22.7k | 8/24/22 | |
| P00003 | Exercise an Option | $22.7k | 7/6/21 | |
| P00002 | Exercise an Option | $22.7k | 5/5/20 |